A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients

Therapeutic Drug Monitoring

Volumn 32, Issue 1, 2010, Pages 86-92

  D'Avolio, Antonio ^a   Simiele, Marco ^a   Baietto, Lorena ^a   Siccardi, Marco ^a   Sciandra, Mauro ^a   Patanella, Samantha ^a   Bonora, Stefano ^a   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

CCR5 inhibitor; High performance liquid chromatographyultraviolet; HIV; Maraviroc; Therapeutic drug monitoring

Indexed keywords

MARAVIROC;

ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; ULTRAVIOLET RADIATION;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANES; DRUG MONITORING; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5; REPRODUCIBILITY OF RESULTS; TRIAZOLES;

EID: 75649121808     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181cacbd0     Document Type: Article

References (26)

1. Taiwo BO, Hicks CB. Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance. AIDS Read. 2007;17: 151-161.
2. Correll T, Klibanov OM. Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection. Pharmacother-apy. 2008;28:90-101.
3. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable Antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection-Results of a 48-week controlled study. JAIDS J Acquir Immune Defic Syndr. 2007;46:125-133.
4. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48:4680-4686.
5. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39-48.
6. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29-38.
7. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol. 2005;79:12773-12782.
8. Este JA, Telenti A. HIV entry inhibitors. Lancet. 2007;370:81-88.
9. Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005;11:1170-1172.
10. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429-1441.
11. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008; 359:1442-1455.
12. Yost R, Pasquale TR, Sahloff EG. Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection. Am J Health Syst Pharm. 2009;66:715-726.
13. Dhami H, Fritz CE, Gankin B, et al. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies. J Clin Pharm Ther. 2009;34:147-160
14. Pfizer Italia srl. Maraviroc Investigator Brochure. 2008: Maraviroc Investigator Brochure-Edition 1.0.
15. Macarthur RD, Novak RM. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis. 2008;47: 236-241.
16. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 2002;16(Suppl 1): S5-S37.
17. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit. 2006;28:468-473.
18. Gazzard B. guidelines for the treatment of HIV-infected adults with antiretroviral therapy British HIVAssociation (BHIVA) (2005). HIV Med. 2005;6 (Suppl 2):1-61.
19. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006) 1. HIV Med. 2006;7:487-503.
20. Siccardi M, D'Avolio A, Nozza S, et al. Is Maraviroc a substrate for SLCO1B1? 10th International Workshop on Clinical Pharmacology oh HIV Therapy. Amsterdam, The Netherlands: April 15-17, 2009;27-28.
21. Fayet A, Beguin A, Zanolari B, et al. A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:1057-1069.
22. Notari S, Tommasi C, Nicastri E, et al. Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV. IUBMB Life. 2009;61:470-475.
23. Center for Drug Evaluation and Research of the U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry Bioanalytical Method Validation [FDA web site], May, 2001. Available at: http://www.fda.gov/cder/guidance/4252fnl.htm. Accessed July 20, 2009.
24. D'Avolio A, Baietto L, Siccardi M, et al. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit. 2008;30:662-669.
25. KKGT Web. International Interlaboratory Control Program For Therapeutic Drug Monitoring In HIV Infection, 2009. Available at: www.kkgt.nl. Accessed July 20, 2009.
26. TDM Torino Web. Therapeutic Drug Monitoring Website. Laboratory of Clinical Pharmacology and Pharmacogenetics. University of Turin/ASL TO2, 2009. Available at: www.tdm-torino.org. Accessed July 20, 2009.